Sigachi Laboratories Unlisted Shares
Sigachi Laboratories is a Hyderabad-based bulk drug and drug intermediates company. It has leased out both of its factories in Telangana, and earns most of its income from lease rent, interest and dividends.
Read the full company profileSigachi Laboratories share details
- Lot size
- 1,000 shares
- Min. investment
- ₹52,000
- Face value
- ₹10
- Implied market cap
- ₹35 Cr
- Shares outstanding
- 6,753,100
- Founded
- 1994
- Headquarters
- Hyderabad, Telangana
- ISIN
- INE368H01018
- CIN
- L24230TG1994PLC018786
- Lock-in after IPO
- 6 months
Sigachi Laboratories share price chart
Indicative off-market dealer quotes, not exchange prices. A flat stretch means the quote did not change on those days.
About Sigachi Laboratories
Strengths
- The company has no borrowings. The balance sheet at 31 March 2026 shows nil borrowings against total equity of ₹4,088.34 lakh.
- Profit grew in FY26. Profit for the year was ₹133.97 lakh against ₹119.10 lakh in FY25, and net profit margin was 33.45% against 31.49%.
- Cash generated from operations helped. Net cash from operating activities was ₹155.99 lakh in FY26 against ₹52.17 lakh in FY25, which is more than the profit for FY26.
- Liquidity is comfortable on paper. The current ratio was 36.09 at 31 March 2026, as current liabilities were only ₹11.76 lakh.
- Both factories are leased for a 15 year term from 01-05-2025, which gives a fixed rent stream.
- The company holds financial investments of ₹3,144.68 lakh (non-current) and receives dividends and interest from them.
Risks
- The company depends on lease rentals from only one party, as the management itself states in the annual report.
- The business is very small. Revenue from operations was ₹325.75 lakh in FY26, so any problem with the tenant would hit the whole income.
- A large part of profit comes from non-operating items. Other income was ₹74.73 lakh in FY26 and fair value losses of ₹129.23 lakh were charged, so profit can swing with market values.
- The company has given demand loans or inter-corporate deposits to some parties, and it took an impairment of ₹75.00 lakh on advances in FY25.
- Trade receivables rose to ₹97.38 lakh from ₹2.78 lakh, and the debtors turnover ratio fell by 74.67%.
- Promoter and promoter group hold 36.98%, and the company rents its corporate office from a relative of the Executive Director, so related-party dealings exist.
- No mutual fund or foreign portfolio investor holds shares, and off-market prices are indicative and not set on an exchange, so the price shown may not match a trade you can get.
- Capital work in progress was ₹202.53 lakh at 31 March 2026, and cash fell to ₹33.48 lakh from ₹186.48 lakh.
Sigachi Laboratories financial performance
Revenue, profit and balance-sheet figures by fiscal year.
| Metric | FY26Latest | FY25 |
|---|---|---|
| Revenue (₹ Cr) | 3.26 | 3.12 |
| PAT (₹ Cr) | 1.34 | 1.19 |
| PAT Margin (%) | 41.10 | 38.14 |
| RoNW (%) | 3.28 | 3.03 |
| EPS (₹) | 1.98 | 1.76 |
| Total Assets (₹ Cr) | 42.66 | 40.91 |
| Net Worth (₹ Cr) | 40.88 | 39.33 |
Swipe the table sideways for earlier years →
Management team
Buy or sell Sigachi Laboratories unlisted shares
Get a live quote on WhatsApp in under 60 seconds. Current price ₹52.00. Shares are delivered to your own demat in 24–48 hours, never to a custodian.
Indicative off-market price, not an exchange quote. Read the disclaimer.
Sigachi Laboratories unlisted shares: common questions
Important disclaimer
Unlisted shares are not traded on stock exchanges. Prices shown are indicative and based on off-market transactions; they may differ from eventual listing or future market prices. Exit liquidity depends on counter-party availability. SEBI mandates a 6-month lock-in on pre-IPO shares post-listing. Gains held beyond 24 months are taxed at 12.5% LTCG (no indexation). IPO Guru is not a SEBI Registered Investment Advisor. Information here is for general awareness, not personalised investment advice. Please consult your tax advisor before investing.
